Nuclear Play for 2026 and Beyond: Should You Buy Cameco Stock While It's Below $125?

Cameco, the world's second-largest uranium producer, supplied roughly 160 million pounds (17% of global output) in 2024 and controls two of the highest-grade uranium deposits—Cigar Lake and McArthur River—giving it lower refining costs versus lower-grade competitors. The company holds a 49% stake in Westinghouse (AP1000 reactor) and benefits from rising U.S. nuclear commitments and corporate demand (cited AI-driven power needs), while its financials show accelerating revenue growth (10-year CAGR 2.6%; 3-year CAGR 24.2%) and strong profitability (gross margin 36.3%, net margin 15.2%); Canadian uranium received a tariff carveout, enhancing U.S. market access. These fundamentals and strategic positioning underpin the article's bullish investment case and recent outperformance versus the S&P 500.

Analysis

Market structure: Nuclear-focused winners are high‑grade uranium producers (CCJ: 17% global share, 160M lb in 2024) and reactor/IP partners (Westinghouse exposure via CCJ, plus CEG/NEE as utility off-takers). Pricing power shifts toward high‑grade, low‑cost producers because their marginal cost is materially lower than Kazakhstan/low‑grade supply, compressing break‑even for new entrants and raising spot/term price floors for uranium over multi-year build cycles.

Risk assessment: Tail risks include a regulatory reversal or tariff reintroduction, a major operational shutdown at Cigar Lake/McArthur River, or a sudden release of secondary inventories that could drop spot uranium >30% in weeks. Immediates (days) will be sentiment-driven; weeks–months hinge on contract announcements and DOE milestones; quarters–years depend on AP1000 build timelines and utility long‑term contracting; hidden dependency: CCJ’s Westinghouse stake links mining cashflow to construction execution and capex volatility.

Trade implications: Direct play is CCJ equity and defined‑risk options — fundamental upside from accelerating revenue CAGR (24% last 3 years) but lumpy demand; expect elevated implied vols around DOE/reactor milestones, creating opportunities for 9–18 month call spreads and covered calls if funded. Cross‑asset: increased utility nuclear capex will pressure long‑dated IG issuance (more supply in 5–10y market) and raise correlations between uranium equities and long‑dated utilities' credit spreads.

Contrarian angles: Consensus underestimates inventory/contracting lags — utilities may front‑load hedges leading to choppy spot moves; the market may already price long‑term policy rather than near‑term deliveries, so a 20–40% pullback is plausible if AP1000 schedules slip. Historical parallels: reactor/build cycles (1970s–80s) show policy announcements often precede multi‑year execution slippage; unintended consequence: CCJ could inherit Westinghouse execution risk that transiently de-rates the miner despite strong uranium fundamentals.

Key Decisions for Investors

• Establish a 2–3% portfolio long in CCJ shares within the next 30 trading days, averaging in on any pullbacks of 8–12% from the 30‑day high; add a tactical 12–18 month call spread (buy 1 LEAP ATM, sell 1 30–40% OTM) sized at 0.5–1% notional to lever upside with defined risk.
• If uranium spot price sustains >$100/lb for 30 consecutive days or CCJ announces multi‑year take‑or‑pay contracts, increase CCJ exposure to 4–6% and roll longs into Jan 2028 LEAPS; conversely, trim CCJ by 50% if spot falls >25% in a 30‑day window or if Westinghouse/AP1000 construction cancellations are announced.
• Rotate 1–2% of equity allocation from gas‑merchant power producers into nuclear‑exposed utilities (CEG, NEE), buying CEG/NEE on dips of 5–10% over the next 3 months to capture data‑center baseload demand; hedge execution risk by buying 9–12 month puts equal to 25% of new position size.
• Execute a relative value pair: long CCJ (2%) and short a speculative uranium junior explorer (or ETF tracking juniors) (1%) to capture spread compression if high‑grade producers re‑rate; maintain stop‑loss at 20% adverse move on the pair and re‑evaluate after DOE/AP1000 milestone updates within 6 months.